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Research on the use of human papillomavirus (HPV) DNA testing
in the screening and management (triage) of cervical lesions began
in the late 1980s with the growing evidence that certain (high-risk
(HR)) HPV types were the cause of cervical cancer (Walboomers
et al, 1999; IARC, 2005). Since women not infected with HR HPV
types, even with abnormal cytology, are at negligible risk for
cervical cancer, HPV testing could be superior to cytology in
cervical cancer screening (Cuzick et al, 1999; Nobbenhuis et al,
1999). Human papillomavirus testing may also be cost-effective if
it allows for a longer screening interval, or for screening to be
discontinued at an earlier age than currently recommended (i.e., 65
years). Follow-up studies of women with negative cytology,
according to HPV status, are therefore important. In this issue,
Bulkmans et al (2005) and Grainge et al (2005), using two different
study designs, provide further evidence of the value of adding HPV
testing to cervical cytology in screening programmes.
In their 5-year cohort study in The Netherlands of 2810 women
aged 30–60 years with normal cytology, Bulkmans et al (2005)
show that, in agreement with previous findings from the US
(Sherman et al, 2003), France (Clavel et al, 2004) and the UK
(Cuzick et al, 2003; Peto et al, 2004), HR HPV testing combined
with cytology has higher sensitivity and higher negative predictive
value for cervical intraepithelial neoplasia (CIN) 3 and cancer than
cytology alone. Specificity was, however, slightly lower for HPV
testing and cytology (93%) than cytology alone (95%).
The improvement in sensitivity and negative predictive value
made possible by the addition of HR HPV testing to cytology
supports the use of viral testing in order to increase the screening
interval, although the findings of Bulkmans et al (2005) should be
interpreted with some caution as their study was relatively small,
and, as the authors emphasise, an increased sensitivity is implicit
in performing any additional test (Franco and Ferenczy, 1999).
Also in this issue, Grainge et al (2005) report the findings of a
nested case–control study based on women with a normal
cytological smear between 1988 and 1992 (termed the baseline
smear) who later, after an average of 6.8 years, received a
histologically confirmed diagnosis of CIN 2 or worse. Excluding
CIN2, which is biologically and clinically difficult to distinguish
from CIN1, there were 346 CIN3 cases and 51 cervical cancer cases
together with 591 control women who never had cytological
abnormalities. Although Grainge et al (2005) found a significantly
higher HPV positivity among cases compared to controls, a
substantial proportion of women tested negative for HPVs in
baseline smears less than 4 years (67%), and 4–13 years (74%),
before the diagnosis of CIN3/cervical cancer. Unfortunately, such
use of long-stored archived cervical smears is prone to the danger
of false-negative HPV findings (De Roda, 1995) and cross-
contamination (Chua and Hjerpe, 1995).
It is important to bear in mind, however, that the detection of
HPV at a single point in time (as in case–control studies) or over a
few years of follow-up (seldom more than 5 years in available
cohort studies, Schiffman et al, 2005) does not allow an accurate
estimate of a woman’s lifelong risk of HPV infection nor of cervical
cancer. Transiently detectable HPV infection is generally regarded
as harmless, but the long-term prognosis of an HPV-positive
finding is not fully understood. A follow-up study of 232 women
with HR HPV infection in Manchester, UK, showed a cumulative
rate of CIN3 or worse of 16% after 10 years (Peto et al, 2004).
A lower CIN3 rate (6%) was seen in the Portland study in the
US (Sherman et al, 2003), in which women were examined,
biopsied and treated more frequently than in the Manchester
study.
At least two important issues are, therefore, still open: (a)
whether HPV infection disappears or, in some instances, persists
undetectably in the basal cells of the cervix, and (b) whether HR
HPV infection without cervical abnormality should be observed or
treated, and if so, when and how. These uncertainties must be
resolved before HPV testing can replace cytology and new
recommendations made about screening interval or early screen-
ing cessation (Peto et al, 2004).
Several large-scale randomised controlled trials are ongoing on
these issues and their final results should become available within
the next 2 or 3 years (Dillner, 2000; Bulkmans et al, 2004; Kitchener
et al, 2004; Ronco et al, 2004). For the moment it is important to
avoid the so-called ‘implement now and trust’ approach (Whynes,
2004). Apparent coincidence of interests between manufacturers,
who see an enormous market for HPV tests, and women and
physicians, who would favour any extra test for added reassurance,
should not distract from the evaluation of the real benefit of using
HPV testing in cervical cancer screening and its associated
financial and emotional cost. Most importantly, enthusiasm for
new technology should not eclipse the well-known requirements
for good screening programmes, namely high coverage, quality
control and follow-up (IARC, 2005).
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